I was willing to let in roll but, today I went through the...

First 5 Last

Share
Profile

Follow
Eaglebird

909 Posts.

69

28/09/18

16:34

Post #: 35915579
Share

Originally posted by Researcher101 ↑

The board and Snr management of Vivid appear to be managing the capital position of this company on an adhoc basis with complete disregard for the long term survival of this company. What are they thinking?

1. On 31 July 2018 the company announces a convertible note for $1.5m. The announcement stated that the size of the facility could be increased by consent of the lender (Evercharge Pty Ltd) (One wonders if they refused to provide additional credit and so the company had to deal with different shareholders?)

2. On 27 September 2018 the company announces a further convertible note of $1.3m with the capacity to increase it to $2.0m to 'different shareholders' BUT only 1.3m of funding had been secured.

The $2.8m of convertible notes with capacity to extend it to $3.5m is NOT an adequate long term solution to what is clearly an extremely capital intensive business.

The recent fall in the share price can hardly be surprising, and the inevitable capital raise is going to be painfully diluting.

FY18 revenue from sales $7.26m
FY cost incurred in the sale of inventories $5.23m
Gross Margin is therefore around 39%.
Note there appears to be no economies of scale in this business as FY17 Gross Margin was around 36% on a paltry 2.3m of revenue.

If you look at the other stay in business costs of the company they total around $7.8m of which employee costs are 4.2m (why these are so high is another question that needs to be answered).

In any case ,assuming a Gross Margin of 39% and stay in business costs of $7.8m implies that vivid will have to do around 20m of revenue to break even. This will not happen any time soon - IF EVER?

The company has NO alternative but to CUT COSTS, and these temporary measures of trying to plug cash flow shortfall's but issuing piece meal convertible notes is a JOKE!

At what price are management going to acknowledge that the game is up! This trajectory is not sustainable.

Tick Tock Tick Tock

Expand

I was willing to let in roll but, today I went through the annual report and concluded I am better of tapping out for now.
Like what they offer but, at the end of the day it needs to put money in the bank and that ain't happening.
Will watch for now.

VIV Price at posting: 3.6¢ Sentiment: Hold Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 25 more messages in this thread...

First 5 Last

Add VIV (ASX) to my watchlist

I was willing to let in roll but, today I went through the...

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News